Logo image of CNTA

CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Fundamental Analysis

NASDAQ:CNTA - Nasdaq - US1523091007 - ADR - Currency: USD

13.79  +0.18 (+1.32%)

After market: 13.98 +0.19 (+1.38%)

Fundamental Rating

2

CNTA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. The financial health of CNTA is average, but there are quite some concerns on its profitability. CNTA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTA had negative earnings in the past year.
CNTA had a negative operating cash flow in the past year.
In the past 5 years CNTA always reported negative net income.
CNTA had a negative operating cash flow in each of the past 5 years.
CNTA Yearly Net Income VS EBIT VS OCF VS FCFCNTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -40.87%, CNTA perfoms like the industry average, outperforming 55.03% of the companies in the same industry.
CNTA has a Return On Equity of -58.71%. This is comparable to the rest of the industry: CNTA outperforms 59.96% of its industry peers.
Industry RankSector Rank
ROA -40.87%
ROE -58.71%
ROIC N/A
ROA(3y)-43.83%
ROA(5y)-56.62%
ROE(3y)-62.33%
ROE(5y)-121.67%
ROIC(3y)N/A
ROIC(5y)N/A
CNTA Yearly ROA, ROE, ROICCNTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

CNTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTA Yearly Profit, Operating, Gross MarginsCNTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

CNTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CNTA has been increased compared to 1 year ago.
The number of shares outstanding for CNTA has been increased compared to 5 years ago.
CNTA has a better debt/assets ratio than last year.
CNTA Yearly Shares OutstandingCNTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CNTA Yearly Total Debt VS Total AssetsCNTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CNTA has an Altman-Z score of 3.73. This indicates that CNTA is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.73, CNTA is doing good in the industry, outperforming 78.13% of the companies in the same industry.
A Debt/Equity ratio of 0.27 indicates that CNTA is not too dependend on debt financing.
CNTA's Debt to Equity ratio of 0.27 is on the low side compared to the rest of the industry. CNTA is outperformed by 70.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 3.73
ROIC/WACCN/A
WACC9.34%
CNTA Yearly LT Debt VS Equity VS FCFCNTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 9.25 indicates that CNTA has no problem at all paying its short term obligations.
CNTA has a Current ratio of 9.25. This is in the better half of the industry: CNTA outperforms 76.90% of its industry peers.
CNTA has a Quick Ratio of 9.25. This indicates that CNTA is financially healthy and has no problem in meeting its short term obligations.
CNTA has a better Quick ratio (9.25) than 76.90% of its industry peers.
Industry RankSector Rank
Current Ratio 9.25
Quick Ratio 9.25
CNTA Yearly Current Assets VS Current LiabilitesCNTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CNTA have decreased strongly by -10.19% in the last year.
CNTA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-10.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, CNTA will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.88% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.19%
EPS Next 2Y2.38%
EPS Next 3Y-0.86%
EPS Next 5Y10.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTA Yearly Revenue VS EstimatesCNTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2028 2029 2030 2031 2032 500M 1B 1.5B
CNTA Yearly EPS VS EstimatesCNTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTA Price Earnings VS Forward Price EarningsCNTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTA Per share dataCNTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.38%
EPS Next 3Y-0.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CENTESSA PHARMACEUTICALS-ADR

NASDAQ:CNTA (4/25/2025, 8:00:00 PM)

After market: 13.98 +0.19 (+1.38%)

13.79

+0.18 (+1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24 2025-03-24/bmo
Earnings (Next)N/A N/A
Inst Owners84.89%
Inst Owner Change-75.87%
Ins Owners1.22%
Ins Owner Change-4.91%
Market Cap1.84B
Analysts86.25
Price Target32.39 (134.88%)
Short Float %3.79%
Short Ratio4.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.91%
Min EPS beat(2)-42.51%
Max EPS beat(2)12.7%
EPS beat(4)2
Avg EPS beat(4)-4.84%
Min EPS beat(4)-42.51%
Max EPS beat(4)12.7%
EPS beat(8)5
Avg EPS beat(8)6.19%
EPS beat(12)8
Avg EPS beat(12)4.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.97%
PT rev (3m)11.68%
EPS NQ rev (1m)2.48%
EPS NQ rev (3m)1.16%
EPS NY rev (1m)1.61%
EPS NY rev (3m)2.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.57
P/tB 4.57
EV/EBITDA N/A
EPS(TTM)-1.73
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0
BVpS3.01
TBVpS3.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.87%
ROE -58.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.83%
ROA(5y)-56.62%
ROE(3y)-62.33%
ROE(5y)-121.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.61%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.25
Quick Ratio 9.25
Altman-Z 3.73
F-Score4
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)300.47%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
EPS Next Y11.19%
EPS Next 2Y2.38%
EPS Next 3Y-0.86%
EPS Next 5Y10.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.32%
EBIT Next 3Y-16.73%
EBIT Next 5YN/A
FCF growth 1Y11.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.41%
OCF growth 3YN/A
OCF growth 5YN/A